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Abstract 34 
 1 
Eight syndromes are associated with loss of methylation at specific imprinted loci. There 35 
has been increasing evidence that these methylation defects are not isolated events 36 
occurring at a given disease-associated locus but that some of these patients may have 37 
multi-locus imprinting disruptions (MLID) affecting additional imprinted regions. 38 
 With the recent advances in technology, methylation profiling has revealed that 39 
imprinted loci represent only a small fraction of the methylation differences observed 40 
between the gametes. To figure out how imprinting anomalies occur at multiple imprinted 41 
domains, we have to understand the interplay between DNA methylation and histone 42 
modifications in the process of selective imprint protection during pre-implantation 43 
reprogramming, which if disrupted leads to these complex imprinting disorders.  44 
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Life cycle of Imprints. 49 
DNA methylation on imprinted differentially methylated regions (DMRs) is transmitted to 50 
the embryo from the gametes, where the asymmetrical marking is established during 51 
gametogenesis. Studies in mice reveal that DNMT3L regulates the de novo methylation 52 
activity of DNMT3A on DMRs by stimulating its enzymatic activity and facilitating 53 
binding to unmodified H3K4 (H3K4me0) [1-5]. During epigenetic reprograming in the 54 
embryo imprinted methylation is protected against erasure and is subsequently maintained 55 
by DNMT1-UHRF1 [6-7](Figure 1). Two proteins have been implicated in the 56 
maintenance of the maternal and paternal DNA methylation at DMRs, DPPA3 (also known 57 
as PGC7/Stella) and the KRAB zinc finger protein ZFP57 protein, both of which are 58 
conserved between mice and humans [8, 9](Figure 2).  Conversely to the demethylation 59 
wave in the pre-implantation embryo, there is a de novo DNA methylation wave at the time 60 
of implantation from which the unmethylated alleles of DMRs require protection, which 61 
has been shown to involve CTCF, OCT4 and the permissive histone modification 62 
H3K4me2/3 [10-12].  63 
 64 
 65 
 66 
Imprinting disorders and aberrant DNA methylation. 67 
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Alterations in any of the above processes can lead to aberrant imprinting, which can result 68 
in either the reactivation of the original silent allele or the silencing of the previously active 69 
allele. Since methylation profiles are faithfully copied during replication, an abnormal 70 
imprinted methylation profile will be maintained through somatic development and be 71 
present in multiple tissues. If methylation defects occur in only a few cells of the pre-72 
implantation embryo, then somatic mosaicism will result [13]. 73 
 It is currently unknown if the DNA methylation defects associated with imprinting 74 
syndromes are due to primary epimutations that result from the direct disruption of 75 
methylation at imprinted DMRs, which may be influenced by transient environmental 76 
exposures, or to secondary epimutation resulting from an initial genetic mutation in a cis-77 
acting element or trans-acting factor involved in establishment or maintenance of imprinted 78 
methylation.  79 
 80 
Multi-locus imprinting defects by ID: 81 
Chromosome 6q24- TNDM. 82 
Transient Neonatal Diabetes Mellitus (TNDM, OMIM 601410) is caused by loss of 83 
imprinting of the PLAGL1 domain (LRG_1035), with affected patients suffering from 84 
severe intrauterine growth restriction [14] and transient neonatal diabetes mellitus that often 85 
becomes permanent in teenage years. Approximately half of the patients with PLAGL1 86 
methylation defects also have additional hypomethylation of other maternally methylated 87 
imprinted regions. Mackay and colleagues coined the term “maternal hypomethylation 88 
syndrome” [15], with the same group identifying recessive mutations of ZFP57 in TNDM 89 
cases associated with hypomethylation of PLAGL1 and invariably GRB10 and PEG3 [16-90 
18]. Interestingly individuals with multi-locus imprinting disturbances (MLID) without 91 
ZFP57 mutations were more severely affected than those with ZFP57 aberrations, with 92 
additional DMRs (DIRAS3, IGF2R, MEST, KCNQ1OT1, IGF1R, ZNF331, WRB and 93 
SNU13) frequently being hypomethylated [17, 18]. However it must be noted that these 94 
observations are based on genome-wide methylation screening using high-density or 95 
imprint-targeted arrays in only two ID cohorts, so the frequency and affected loci may 96 
change with additional investigations. 97 
 At the phenotypic level, the cases of MLID associated with TNDM are largely 98 
indistinguishable from other TNDM subgroups [15, 19]. However, subtle heterogeneous 99 
non-diabetes features such as learning difficulties, hypotonia, macroglosia, umbilical hernia 100 
and congenital heart disease may occur more frequently in those with MLID [17, 19, 20]. 101 
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All of the 14 cases reported with ZFP57 mutations seemed to follow the classical 102 
progression of the disease and any phenotypic differences between ZFP57 mutated and 103 
idiopathic MLID cases may be due to additional deleterious variants in these highly 104 
consanguineous families.  105 
 106 
Chromosome 11p15- BWS. 107 
Beckwith-Wiedemann syndrome (BWS, OMIM 130650) is a growth disorder characterized 108 
by macrosomia, macroglossia, visceromegaly, ear creases, hypoglycemia, hemihypertrophy 109 
and abdominal wall defects with an increased risk of pediatric tumours [21]. The molecular 110 
alterations in BWS involve two separate imprinted domains on chromosome 11, with 111 
sporadic hypomethylation of the KCNQ1OT1 DMR (also known as KvDMR1, ICR2) 112 
(LRG_1052) being the most frequently observed. A gain of methylation at the H19 113 
intergenic DMR (LRG_1030) is detectable in ~5% of cases, with the remainder of BWS 114 
individuals having paternal uniparental disomy of 11p15 or CDKN1C mutations 115 
(LRG_533) [22, 23].   116 
 The first molecular confirmation of MLID involving the chromosome 11p15 locus 117 
described two TNDM patients with hypomethylation of both the PLAGL1 and KCNQ1OT1 118 
DMRs [24].  Interestingly, one of these TNDM patients had UPD(6)pat, the other a 119 
epimutation of the PLAGL1 DMR. This second patient presented with classic TDNM 120 
complicated with umbilical hernia and macroglossia, features commonly seen in patients 121 
with BWS. Following this study several groups confirmed MLID in BWS cohorts, with a 122 
frequency of up to 30% of those individuals with an underlying KCNQ1OT1 methylation 123 
defect [17, 18, 25-30]. Two recent papers have described methylation anomalies at 124 
additional imprinted loci in patients with H19 hypermethylation [31, 32]. The MLID 125 
observed in BWS are notably different from those observed in TNDM, with both gains and 126 
losses of methylation observed at maternal and paternal DMRs. The paternally methylated 127 
DMRs associated with ZBDF2, NESP and ZNF597/NAA60 have been shown to gain 128 
methylation in subsets of BWS patients [17, 31]. This acquisition is due to a concomitant 129 
loss of methylation in the nearby maternally methylated GPR1-AS, GNAS and ZNF597 130 
DMRs, which are known to regulate the methylation of these somatic DMRs in a 131 
hierarchical fashion [12, 33, 34]. 132 
 Although the techniques used to determine MLID vary between laboratories, it 133 
seems that the DMRs associated with PLAGL1, GRB10, MEST, GNAS, IGF2R and ZNF331 134 
are the most frequently disrupted in BWS with MLID (Figure 3) [17, 18, 30]. The 135 
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maternally methylated region within intron two of IGF2R has been observed to be hypo- or 136 
hypermethylated in BWS and TNDM patients [17, 18, 30] with lower rates observed in 137 
control individuals [30], suggesting that this may be in part a stochastic event. 138 
 Numerous studies have revealed LOM of the H19 and KCNQ1OT1 DMRs 139 
coexisting in the same patient. Hypomethylation at H19 is normally associated with growth 140 
restriction associated with SRS, while KCNQ1OT1 hypomethylation is associated with 141 
macrosomia [17, 26, 35]. It is unclear why different patients with apparently similar 142 
patterns of LOM in these two loci may have different predominating presentations.  It has 143 
been proposed that the dominant phenotype is defined by the locus with the most severe 144 
hypomethylation or the most affectedness in a target organ [13].  This may not always be 145 
apparent by molecular testing, which is often performed on blood-derived DNA. 146 
 Complex phenotypes may also be observed when loci other than H19 and 147 
KCNQ1OT1 are involved. Recently BWS and PHP1B were described in a single patient 148 
with MLID [36].  Alternatively, one phenotype can dominate over another: for example, an 149 
infant with severe LOM at both PLAGL1 and KCNQ1OT1 presented neonatally with BWS 150 
and without neonatal diabetes, but later relapsed with adult diabetes (D Mackay, personal 151 
communication).  However, not all BWS cases with hypomethylation of PLAGL1 or GNAS 152 
have a history of TNDM or pseudohypoparathyroidism, respectively [17, 26, 35].  In a 153 
patient with a clinical diagnosis a BWS after assisted reproductive technology, Lim et al 154 
[27] found normal methylation at KCNQ1OT1 DMR but LOM at H19, PLAGL1 and MEST 155 
DMRs. In sum, the clinical presentation of a MLID patient probably reflects the severity 156 
and tissue mosaicism of hypomethylation in different tissues; but further molecular and 157 
clinical research is needed to understand and predict the resultant phenotypes in different 158 
individuals. 159 
 For the majority of BWS patients with MLID no additional clinical features have 160 
been noted [30, 35]. Two studies with deep phenotyping data suggest that developmental 161 
delay and abnormal glycemic control are slightly more prevalent in those patients with 162 
additional loci affected, as are additional congenital abnormalities [17, 29]. 163 
 164 
Chromosome 11p15- SRS. 165 
Silver Russell syndrome (SRS, OMIM 180860) is a clinically heterogeneous disorder 166 
characterized by severe IUGR, postnatal growth failure, craniofacial features such as a 167 
triangular shaped face and broad forehead, body asymmetry and a variety of minor 168 
malformations. In ~40% of patients hypomethylation of the H19 intergenic paternally 169 
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methylated region is observed [37].  MLID has been described in ~15% of SRS cases with 170 
H19 hypomethylation with common deregulated methylation at DIRAS3, PLAGL1, GRB10, 171 
MEST, IG-DMR, ZNF331, WRB and SNU13 DMRs (figure 3) [17, 18 35, 38, 39]. 172 
Therefore, similar to BWS cases with MLID both paternally and maternally methylated 173 
DMRs are affected. Remarkably, the hypomethylation observed in SRS is often less severe 174 
when compared to other IDs with MLID, an observation probably associated with the high 175 
levels of mosaicism reported.  176 
 Recently several SRS patients have been reported with hypomethylation of both 177 
H19 and KCNQ1OT1 DMRs. In 2011 Begemann and coworkers reported the molecular 178 
findings in three cases, with one child also having hypomethylation of the MEST DMR 179 
[38]. It is striking that, apart from one patient having an umbilical hernia these three 180 
children did not present with any phenotypic features consistent with BWS. 181 
 In most cases the SRS phenotypes are grossly indistinguishable between isolated 182 
H19 hypomethylation and individuals with MLID [17, 35]. However in two large studies it 183 
was suggested that SRS with MLID have less severe growth phenotypes and an increased 184 
prevalence of developmental delay and other congenital abnormalities [29].  185 
 Two individuals with epimutation of the IG-DMR and MEG3 promoter at the 186 
14q32.2 imprinted domain, a region associated with Temple syndrome (TS, OMIM 187 
616222)[40], have been reported with SRS-compatible phenotypes [41].  Both syndromes 188 
have largely overlapping phenotypic features including low birth weight, relative 189 
macrocephaly, body asymmetry and feeding difficulties. A SRS patient with UPD7mat is 190 
also described with hypomethylation within the chromosome 14 imprinted domain [42]. 191 
This report highlights that two of the molecular mechanisms giving rise to the same 192 
phenotype have occurred in parallel. This may represent a coincidence, but it may also 193 
suggest the two loci either physical interact as has been reported for other imprinted 194 
domains [43] or that a trans-acting factor specific for paternally methylated loci is 195 
involved.  196 
 197 
Chromosome 20q13- PHP. 198 
Pseudohypoparathyroidism (PHP) is a rare disorder typified by hypocalcaemia, 199 
hyperphosphataemia and elevated parathyroid hormone levels. The main imprinted form of 200 
the disease is PHP1B (OMIM 603233), characterized by PTH and sometimes TSH 201 
resistance. The majority of cases are sporadic, with PHP1B subjects displaying 202 
paternalization of the maternally methylated DMRs within the GNAS locus on human 203 
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chromosome 20 (LRG_1051) suggesting that imprinting alterations are the basis of the 204 
disorder since no cis-acting causes have been reported [44, 45].  MLID in sporadic patients 205 
is rare, but when methylation changes are observed they are often mild and affect isolated 206 
additional DMRs (Figure 3) [17, 46-48]. These additional methylation defects have not 207 
been reported to influence growth trajectories, BMI or biochemical measurement. One 208 
fascinating observation gained from these studies is that methylation defects at the GNAS 209 
locus are frequently observed in BWS with MLID with normal hormonal levels, whereas 210 
epimutated PHP cases rarely have MLID.  211 
 212 
MLID in other imprinting disorders. 213 
Very little is known about the frequency of MLID in Angelman syndrome (AS, OMIM 214 
105830), Prader-Willi (PWS, OMIM 176279), Temple or Kagami-Ogata (KOS, 215 
OMIM60814) syndromes because either epigenetic anomalies in these patients are rare 216 
(<5% for AS and PWS) or the disorder itself is so rare that cohort-based studies are 217 
difficult. To date, no cases of MLID have been reported KOS with epimutations at the 218 
chromosome 14-imprinted domain and only a single case for TS with additional 219 
hypomethylation of the KCNQ1OT1 and WRB DMRs [49]. Four patients with features of 220 
PWS but molecular diagnosis of AS have been reported in literature, a situation termed 221 
“Prader-man” [50-52]. These cases presented with partial loss of methylation of the SNRPN 222 
DMR.  The only two reported AS case with MLID have been reported. The first presented 223 
with additional hypomethylation of KCNQ1OT1, PEG3 and GNAS and was reported to 224 
have a complex phenotype overlapping with BWS and PWS [53] and the second having 225 
hypomethylation at DIRAS3, RB1, IGF1R, ZNF331 and GNAS along with ZDBF2 226 
hypermethylation [53].  The methylation defects involving the SNRPN DMR are extremely 227 
rare, and only two cases being described, one in a child with MLID and a non-specific 228 
clinical phenotype presentation [54] and the second with TNDM but with no additional 229 
clinical data reported [18]. Therefore SNRPN methylation defects outside the context of AS 230 
and PWS are extremely rare suggesting that this specific DMR may employ a unique 231 
mechanism to protect methylation. Potential candidates are the Rb-binding proteins 232 
ARID4BA/B, which bind specifically to the mouse Snrpn DMR, which when ablated alter 233 
epigenetic modifications including a reduction in trimethylation of histone H4K20 and 234 
H3K9 and DNA methylation on the maternal allele [55]. 235 
 236 
MLID and Assisted Reproductive Technologies.  237 
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There is unequivocal evidence that within AS and BWS populations, isolated LOM of the 238 
SNRPN and KCNQ1OT1 respectively is more prevalent in patients conceived following the 239 
use of assisted reproductive technologies (ART) [27, 56-60]; however it must be noted that 240 
the absolute risk of having a child with an ID following ART is extremely low [61]. Several 241 
cohorts have identified associations between BWS MLID and ART [25-27, 30], but such 242 
associations are not consistent between publications [62]. Furthermore there are conflicting 243 
reports of ART influencing the BWS phenotype, with no significant associations found in 244 
most reports. However, statistical differences were observed for earlobe anomalies, 245 
advanced bone age and congenital heart disease, in one deep-phenotyping study [62]. 246 
 It remains to be determined whether loss of methylation at imprinted DMRs is 247 
associated with the underlying fertility problems or whether this occurs as a consequence of 248 
the treatment or embryo culture. It has recently been reported that embryos with delayed 249 
first cytokinesis and those who took longer to get to the four-cell stage were associated with 250 
both increased aneuploidy and decreased levels of DNMT3B and NLRP5 [63]. Importantly 251 
these observations were independent of the fertility status, suggesting that aberrant 252 
epigenetic and imprinting profiles maybe linked to slower pre-implantation embryo 253 
cleavage rates during the reprograming window. 254 
 255 
Searching for mutations in trans-acting factors. 256 
To identify the underlying genetic insults responsible for MLID numerous studies have 257 
performed candidate gene mutation screening. These studies have focused on ZFP57, 258 
DNMT3L, DNMT1, MBD3, DPPA3, NLRP2, NLRP7, KHDC3L and TRIM28 [13, 26, 31, 259 
38, 64] with very few pathological variants identified, with the exception of ~50% of 260 
TNDM MLID having recessive mutation of ZPF57 [16,17]. 261 
 262 
ZFP57 is required to protect imprinted methylation. 263 
The ZFP57 gene encodes for a krüppel-associated box domain (KRAB) zinc finger protein 264 
and is located on human chromosome 6q22.1 and mouse chromosome 17qB1. Unlike most 265 
ZNF genes, ZFP57 is not a part of a large ZNF-cluster [65]. In mouse, maternal effect 266 
mutations that result in the loss of Zfp57 in the developing zygote (Zfp57-/- F1 from Zfp57 267 
-/+ mothers) are partially lethal, while eliminating both maternal and zygotic function 268 
(Zfp57-/- F1 from Zfp57 -/- mother) causes complete embryonic lethality [9].    269 
 In wild type mouse embryonic stem (mES) cells, Zfp57 and Trim28 bind to all 270 
known imprinted DMRs by recognizing the recurrent methylated [TG]GCCGC motif [66, 271 
 8 
67], suggesting that Zfp57 recruits the corepressor complex that includes the H3K9 272 
methyltransferase Setdb1 and the heterochromatin protein HP1γ to specific target 273 
sequences [66]. Consistent with this, Zfp57 has been shown to be necessary for the 274 
maintenance of allelic DNA methylation and H3K9me3 at imprinted DMRs [9, 66] and to 275 
be involved in silencing of a limited number of non-imprinted loci [67]. Zuo and colleagues 276 
found that re-introducing Zfp57 into knock out mES cells failed to re-establish DNA 277 
methylation at imprinted loci, indicating irreversible loss at these DMRs [68]. 278 
 Females with homozygous or compound heterozygous mutations of ZFP57 have 279 
been reported in 13 families [16, 17, 20, 69]. All of these families were identified with 280 
TNDM as a result of hypomethylation at the PLAGL1 DMR and additional LOM of other 281 
maternally methylated imprinted genes [16-18].  Apart from at the PLAGL1 locus, the 282 
methylation defects appear mosaic, indicating that ZFP57 is involved in the maintenance of 283 
methylation at imprinted regions during pre-implantation reprograming, similar to its 284 
function in mouse. It remains possible that other members of the ZFP57 complex maybe 285 
involved, such as AFF3 (also known as AF4/FMR2), a protein recently shown to bind to 286 
the methylated allele of imprinted DMRs in a Zfp57-dependent fashion [70]. Furthermore, 287 
methylation profiling has identified a folate-sensitive interval upstream of ZFP57 implying 288 
that environmental exposures may influence expression levels [71]. Consistent with the 289 
hypothesis that the ZFP57 promoter may be epigenetically liable to periconceptional 290 
environment is the observation that methylation in the same region is subjected to seasonal 291 
fluctuations in Gambian children [72]. 292 
 293 
Extreme cases of MLID- hydatidiform moles. 294 
Hydatidiform mole (HM) is an aberrant human pregnancy characterized by abnormal 295 
trophoblast proliferation. Complete HMs do not contain any embryonic tissues other than 296 
placental villi, whereas partial HMs may contain other tissues. Sporadic complete HMs are 297 
mostly diploid and androgenetic in origin. Occasionally HM can be recurrent (RHM) and 298 
familial in nature (OMIM 231090) [73] with mutations in two interacting proteins, NLRP7 299 
(NACHT, leucine rich repeat and PYD containing 7) and KHDC3L (previously known as 300 
C6ORF221) being responsible for ~ 80% of biaparental RHMs [74, 75].  301 
 NLRP7 does not have an orthologue in mouse, but is thought to have originated 302 
from an evolutionary duplication of its nearest family member, NLRP2 [76]. Intriguingly, 303 
NLRP2 was shown to be responsible for a single kindred of BWS based on the discovery of 304 
 9 
a frameshift mutation in a homozygous state in an asymptomatic mother with two children 305 
affected with BWS. Upon methylation analysis, these BWS individuals presented with 306 
methylation defects at multiple loci, including KCNQ1OT1 and MEST DMRs [77].  307 
However, since this report, no other cases of IDs were shown to have mutations in NLRP2, 308 
which makes this finding a rare causal event occurring in a small minority of cases. 309 
 310 
Methylation defects associated with maternal effect NLRP7 mutations. 311 
A recent genome-wide methylation screening in NLRP7-mutated molar tissues suggests 312 
that all maternally methylated DMRs lack methylation while the sperm-derived H19 and 313 
IG-DMR are unaffected [78].  This widespread disruption to maternally methylated DMRs 314 
also extends to the newly identified placenta-specific DMRs that orchestrate imprinting 315 
solely in the placenta [12, 78], suggesting that aberrant expression of both ubiquitously and 316 
placenta-specific imprinted transcripts play a role in the pathophysiology of RHMs.  317 
 Recently, a family was described in which two fetuses and one child with SRS-like 318 
features showed mosaic widespread methylation defects, including maternally and 319 
paternally imprinted loci (including GNAS, KCNQ1OT1, L3MBTL, MEG3, NAP1L5, 320 
NNAT, PLAGL1, RB1 and ZNF597) in multiple tissues.  A mutation screening identified a 321 
p.A719V change in NLRP7 in the mother [64]. However, it remains unclear if this 322 
substitution is responsible for the extreme epigenetic aberrations reported. The DNA base 323 
change is a low frequency variant in both 1000 Genome and in the dbSNP databases and 324 
the mother had inherited the change from her mother, indicating that further stochastic 325 
processes would be required in addition to maternal transmission of c.2156C>T.  This 326 
observation raises interesting yet challenging questions with regards to the role of NLRP7 327 
non-synonymous variants in the pathogenesis of RHM. It has recently been observed that 328 
women suffering from other forms of reproductive loss have missense variants in 329 
heterozygous state, suggesting that phenotype variability may frequently be present [79, 330 
80]. It is therefore essential to determine if normal imprinted methylation profiles are 331 
maintained in these non-RHM pregnancy outcomes.  332 
 Exactly how NLRP-KHDC3L complexes are involved in regulating imprinted 333 
methylation is still a mystery, especially since detailed immunostaining for these factors in 334 
early human embryos and oocytes revealed that this protein is exclusively localized to the 335 
cytosekeleton, within the subcortical maternal complex, and not in the nucleus where it 336 
could associate with chromatin and influence methylation [81, 82]. This profile is similar to 337 
the location of DNMT3A and DNMT3B in human oocytes [83], indicating that NLRP-338 
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KHDC3L-complexes may ensure the correct cellular localization and nuclear translocation 339 
during oocyte development. Once in the nucleus, this low abundance complex may 340 
associate to specific DNA sequences by direct interaction with chromatin regulator YY1 341 
[84] or ZBTB16, a methylation-sensitive Krüppel-like zinc finger protein [85].   342 
 343 
A new player- maternal effect mutations in NLRP5. 344 
The reports of MLID in various IDs have lead many researchers to perform exome-345 
sequencing screens for the underlying coding changes. Despite much effort only a few 346 
causative trans-acting mutations have been found. Recently maternal-effect mutations in 347 
NLRP5 in five mothers of individuals affected by MLID have been reported [54]. The 348 
clinical presentation of the offspring was heterogeneous with two probands having SRS, 349 
three with BWS and two with non-specific phenotypes. All women suffered multiple 350 
reproductive losses. Unlike RHM with NLRP7 mutations, these MLID individuals had only 351 
a small number of DMRs affected (H19, PEG3, GNAS, PLAGL1, KCNQ1OT1, GRB10, 352 
MEST and SNRPN in various combinations) with hypomethylation of both maternally and 353 
paternally methylated DMRs consistent with a role in imprint maintenance. It is interesting 354 
to note that variants identified in 2 of the 5 cases involved non-synonymous SNPs listed in 355 
the dbSNP database. In fact NLRP5, 2 and 7 have a large load of non-synonymous SNPs 356 
(182, 153 and 160 respectively) within their ~3 kb coding sequence suggesting that careful 357 
consideration should be given when these variants are observed on both alleles creating a 358 
compound heterozygous state.  359 
 360 
Conclusions 361 
From assessing the methylation profiles of the various IDs, it is now established that with 362 
the exception of TNDM, MLID is not restricted to maternally methylated DMRs but can 363 
also affect paternally methylated loci. Given the co-existence of LOM at both parentally 364 
methylated DMRs and the mosaic status of the defects in the majority of cases, this 365 
confirms that these methylation aberrations occur after fertilization as a consequence of not 366 
maintaining imprinted methylation during pre-implantation epigenetic reprograming.  The 367 
processes that erase the majority of the non-imprinted germline methylation are complex, 368 
with only a few bona fide trans-acting imprinting protection factors known. MLID in 369 
human provides us with a unique opportunity to identify the regulatory mechanisms 370 
involved in maintaining allelic differences in methylation and the factors involved in the 371 
imprinting life-cycle. 372 
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 In the coming years it will be important to determine the degree of methylation 373 
mosaicism in various cell types, whether at a single disease associated locus or in the 374 
context of MLID, as very few epimutated imprinting disorder cases present with absolute 375 
hypo- or hypermethylated DMRs. As with the detection of somatic UPD, contamination of 376 
normal cells is known to decrease the observed frequency of mosaic epimutations, with 377 
levels of methylation in blood not always reflecting that in other tissues which can 378 
worryingly lead to false negative disease diagnosis. 379 
 380 
Trends box.  381 
• Imprinted DMRs represent a small minority of the methylation difference between 382 
gametes, but somatic protection of these elements is essential to avoid developing 383 
imprinting disorders (IDs). 384 
• A subset of patients with IDs have methylation defects at single disease associated 385 
imprinted DMRs, but other individuals may have multi-locus imprinting 386 
disturbances (MLID) affecting additional imprinted regions. 387 
• The frequency and loci involved in MLID varies between IDs, with Beckwith-388 
Wiedemann syndrome presenting with the highest and most severe MLID cases, 389 
whilst this phenomenon has not been reported in Angelman or Temple syndrome 390 
patients. 391 
• To date, mutations in three trans-acting factors (ZFP57, NLRP2 and NLRP5) have 392 
been associated with MLID. 393 
 394 
Outstanding Questions Box  395 
• Are multiple loci involved in mosaic MLID deregulated in the same or different 396 
cells? With the advent of technologies to quantify genome-wide methylation it will 397 
be important to determine the extent of methylation defects in multiple tissues at 398 
single cell resolution.  399 
• How should MLID be defined? Which loci should be tested using which 400 
techniques? 401 
• Since there is a large degree of clinical heterogeneity in IDs, could MLID and 402 
mosaicism prevent some IDs from being correctly diagnosed? 403 
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• Are cases of MLID without known underlying genetic mutations, such as those with 404 
negative exome sequencing results, caused by environmental insults or is genome 405 
sequencing warranted in these cases? 406 
• Does protection of imprints during pre-implantation embryonic reprogramming 407 
involve specific factors that function at different developmental time points? The 408 
identification of such factors, and their spatial expression profile (i.e. after 409 
embryonic genome activation) will help elucidate possible recessive and maternal-410 
effect genes involved in this process. 411 
• Do the additional loci involved in MLID influence the phenotypes of IDs patients in 412 
the long term? For example, will BWS individuals with MLID involving GNAS or 413 
PLAGL1 develop parathyroid problems or early onset adult diabetes? 414 
• Are the epigenetic changes involved in isolated and MLID cases reprogrammed in 415 
the germline so that there is no subsequent risk to the offspring of these individuals? 416 
• There is reported increased prevalence of IDs following assisted reproductive 417 
technologies. Is this true for MLID also? 418 
 419 
Glossary (Terminology and abbreviations, for the benefit of students, 450 words)  420 
Imprinting disorders (IDs): There are eight classical imprinting disorders including 421 
Angelman syndrome (AS), Prader-Willi syndrome (PWS), Beckwith-Wiedemann 422 
syndrome (BWS), Silver-Russell syndrome (SRS), Pseudohypoparathyroidism (PHP), 423 
Transient Neonatal diabetes (TNDM), Kagami-Ogata syndrome (KOS) and Temple 424 
syndrome (TS). All result from abnormal imprinted gene dosage caused by cytogenetic 425 
changes (deletions and duplications), uniparental disomy, coding mutations and epigenetic 426 
defects. The frequency of the cause varies between disorders, but for the purpose of this 427 
review we have focused on those with methylation defects only. 428 
Loss-of-methylation (LOM): Hypomethylation at imprinted differentially methylated 429 
regions (DMRs) occurs on only one allele. The majority of imprinted DMRs are maternally 430 
methylated inheriting methylation from oocytes, with only two known examples of paternal 431 
germline DMRs at the H19-IGF2 loci on chromosome 11 and the IG-DMR on chromosome 432 
14. Full annotation of imprinted DMRs in humans is available at http://www.imprinting-433 
disorders.eu. 434 
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Multi-locus imprinting disturbance (MLID): These are methylation changes, often 435 
hypomethylation, at additional imprinted loci in addition to those classically causing the 436 
ID. 437 
Mosaic methylation disturbances: The vast majority of methylation changes observed in 438 
IDs are not absolute as would be expected for a germline methylation defect (only observed 439 
in recurrent hydatidiform moles with NLRP7 mutations). Rather they may deviate from the 440 
expected ~50% methylation by as little as 10%. This is thought to reflect mosaicism with 441 
some cells maintaining the correct allelic methylation while others are abnormal. 442 
Furthermore DNA-derived from different tissues from the same patient may present with 443 
different LOM patterns. 444 
Embryonic epigenetic reprogramming: Within a few hours of fertilization a wave of 445 
global demethylation ensures that methylation in the blastocysts are at their lowest levels 446 
erasing the majority of this germline epigenetic information compatible with blastomere 447 
totipotency. However the specific sequences associated with imprinted DMRs survive this 448 
reprogramming, through binding specific factors including ZFP57 and DPPA3/STELLA. 449 
 450 
Figure 1. 451 
The life cycle of epigenetic changes at imprinted loci in mouse.  Regions of differential 452 
methylation are established in the germline and protected from pre-implantation 453 
reprogramming by the maintenance factors ZFP57 and DPPA3. The allelic methylation is 454 
then preserved by the semi-conservative action of DNMT1-UHRF1. In primordial germ 455 
cells of the developing embryos the DNA methylation at imprinted DMRs is erased so that 456 
the new profiles can be established according to the sex of the embryo. This complex 457 
procedure involves histone demethylation of H3K4 and the subsequent recognition and 458 
DNA remethylation by the DNMT3L-DNMT3A complex. * Note that DNMT3L is not 459 
expressed in human oocytes suggesting different recruiting methods between species. 460 
 461 
Figure 2. 462 
Schematic showing the complexes involved in protecting imprinted methylation of 463 
pre-implantation reprogramming. (A) DPPA3 selectively binds to YYCAGSCTSS sites 464 
(where Y is cytosine or thymine and S is cytosine or guanine) associated with underlying 465 
H3K9me2 and DNA methylation predominantly observed in the maternal pronucleus 466 
selective protecting methylation from TET3-mediated hydroxylation. (B) Imprinted DMRs 467 
containing the TGCCmethGC hexanucleotide motif are protected from demethylation by the 468 
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ZFP57-TRIM28 complex during pre-implantation reprogramming. DNA methylation and 469 
K3K9 methylation are maintained at these loci by the recruitment of DNMT1 and 470 
SETBD1, respectively. 471 
 472 
Figure 3. 473 
Ideogram showing the positions of known imprinted domains and the frequency they 474 
are hypomethylated in IDs with MLID. The size of the circle is proportional to the 475 
frequency of hypomethylation at each imprinted loci for 10 SRS, 17 BWS, 6 TNDM and 12 476 
PHP patients with MLID.  The white circle depicts the primary DMR associated with each 477 
disorder.  Data taken from studies that assessed a minimum of 10 imprinted DMRs (mainly 478 
those employing the Illumina Infinium HumanMethylation450 BeadChip array), therefore 479 
some inaccuracies may exist due to coverage, molecular or bioinformatics techniques 480 
employed. 481 
 482 
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